Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

targeted therapy
tamoxifen
adenocarcinoma
estrogen receptor-positive breast cancer
er-positive breast cancer
  • 0 views
  • 19 Feb, 2024
  • 131 locations
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

This phase III trial aims to compare the progression free survival (PFS) and safety of fulvestrant or capecitabine as maintenance therapy after first-line combined chemotherapy in hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer.

maintenance treatment
chromogenic in situ hybridization
chemotherapy regimen
alt/ast
epidermal growth factor receptor
  • 0 views
  • 19 Feb, 2024
  • 7 locations
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line …

gilbert's syndrome
adenocarcinoma
ipatasertib
hcg pregnancy test
stage iv breast cancer
  • 0 views
  • 19 Feb, 2024
  • 10 locations
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

measurable disease
solid tumor
screening procedures
stage iv breast cancer
human chorionic gonadotropin
  • 0 views
  • 19 Feb, 2024
  • 5 locations
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4CDK4and CDK6 kinase activity. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 …

gilbert's syndrome
measurable disease
breast neoplasm
stage iv breast cancer
international normalized ratio
  • 0 views
  • 19 Feb, 2024
  • 1 location